CD274 and non-small cell lung carcinoma: Validated biomarkers identified to date that are predictive of responsiveness to immunotherapy in NSCLC include the tumor mutational burden (TMB) and expression of programmed cell death ligand (PD-L1) (Pharaon et al., 2020).